Transcriptomics-based drug repurposing approach identifies novel drugs against sorafenib-resistant hepatocellular carcinoma

Authors

Kelly Regan-Fendt, The Ohio State University
Ding Li, The Ohio State University
Ryan Reyes, The Ohio State University
Lianbo Yu, The Ohio State University
Nissar A Wani, Central University of Kashmir
Peng Hu, The Ohio State University
Samson T Jacob, The Ohio State University
Kalpana Ghoshal, The Ohio State University
Philip R O Payne, Washington University School of Medicine in St. Louis
Tasneem Motiwala, The Ohio State University

Journal

Cancers (Basel)

Publication Date

2020

Volume

12

Issue

10

Document Type

Open Access Publication

DOI

10.3390/cancers12102730

Rights and Permissions

Regan-Fendt K, Li D, Reyes R, et al. Transcriptomics-Based Drug Repurposing Approach Identifies Novel Drugs against Sorafenib-Resistant Hepatocellular Carcinoma. Cancers (Basel). 2020;12(10):E2730. doi:10.3390/cancers12102730

Recommended Citation

Regan-Fendt, Kelly; Li, Ding; Reyes, Ryan; Yu, Lianbo; Wani, Nissar A; Hu, Peng; Jacob, Samson T; Ghoshal, Kalpana; Payne, Philip R O; and Motiwala, Tasneem, "Transcriptomics-based drug repurposing approach identifies novel drugs against sorafenib-resistant hepatocellular carcinoma." Cancers (Basel). 12, 10. (2020).
https://digitalcommons.wustl.edu/open_access_pubs/9651